Together, these results indicate that our ADAM9-MSNs also release their cytotoxic contents in undesired cellular contexts, which suggests that the ADAM9-MSNs are most likely to not reduce neuropathy and leukopenia in a clinical setting. This evidence concerns the gene ADAM9 and neuropathy.